Filing Details
- Accession Number:
- 0001179110-16-022918
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-04-08 16:02:47
- Reporting Period:
- 2016-04-06
- Filing Date:
- 2016-04-08
- Accepted Time:
- 2016-04-08 16:02:47
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1280600 | Acceleron Pharma Inc | XLRN | Biological Products, (No Disgnostic Substances) (2836) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1325710 | L Matthew Sherman | 128 Sidney Street Cambridge MA 02139 | Evp & Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2016-04-06 | 2,080 | $32.00 | 95,524 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2016-04-07 | 14,000 | $5.08 | 109,524 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2016-04-07 | 23,920 | $32.00 | 85,604 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Option to Purchase Common Stock | Disposition | 2016-04-07 | 14,000 | $0.00 | 14,000 | $5.08 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 5,896 | 2018-03-27 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 8,500 | Indirect | By GRAT |
Footnotes
- The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- The options of registrant's common stock vested in equal quarterly installments over the first four years after the grant.
Billionaire Hedge Funds
